Travere Therapeutics (TVTX) CFO records planned stock sales

Rhea-AI Filing Summary

Travere Therapeutics, Inc. chief financial officer Christopher R. Cline reported two open‑market sales of company common stock on February 4, 2026. He sold 1,635 shares at a weighted average price of $32.14 and 110 shares at $32.90, and continued to hold 111,226 shares directly afterward.

According to the filing, these transactions were executed under a pre‑established Rule 10b5‑1 trading plan adopted on May 28, 2025, and include sales to cover tax obligations arising from the vesting of restricted stock units.

Insights

Equity compensation and insider-transactions analyst

Routine CFO stock sales under a pre-set 10b5-1 plan, with shares remaining substantial.

Travere Therapeutics chief financial officer Christopher R. Cline reported selling 1,635 and 110 common shares on February 4, 2026 at prices around $32 per share. After these transactions, he still directly owned 111,226 shares, indicating an ongoing equity stake.

The filing states the sales were executed under a Rule 10b5-1 plan adopted on May 28, 2025. Such plans allow insiders to prearrange trades, helping separate personal diversification and tax management from day-to-day corporate developments.

The footnote also explains that part of the sale covered tax obligations tied to vesting restricted stock units. This points to standard equity compensation administration rather than a discretionary reduction in ownership. Overall, the activity appears routine and does not on its own signal a change in the company’s outlook.

Insider Trade Summary

Net Seller: 1,745 shares ($56,168)

Net Sell 2 txns

Insider Cline Christopher R.

Role CHIEF FINANCIAL OFFICER

Sold 1,745 shs ($56K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,635	$32.14	$53K
Sale	Common Stock	110	$32.90	$4K

Holdings After Transaction: Common Stock — 111,336 shares (Direct)

Footnotes (1)

1. This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. The weighted average sale price for the transaction reported was $32.14, and the range of prices were between $31.645 and $32.645. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cline Christopher R.

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, STE 300

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/04/2026		S(1)		1,635	D	$32.14(2)	111,336	D
Common Stock	02/04/2026		S(1)		110	D	$32.9	111,226	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

2. The weighted average sale price for the transaction reported was $32.14, and the range of prices were between $31.645 and $32.645. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Travere Therapeutics (TVTX) report for its CFO?

Travere Therapeutics reported that CFO Christopher R. Cline sold common stock in two transactions on February 4, 2026. He sold 1,635 shares at a weighted average price of $32.14 and 110 shares at $32.90, and continued to own 111,226 shares afterward.

Was the Travere Therapeutics CFO stock sale part of a Rule 10b5-1 trading plan?

Yes. The filing states the sale was made under a written trading plan adopted on May 28, 2025 that meets Rule 10b5-1(c) requirements. Such pre-arranged plans help separate routine insider transactions from decisions based on nonpublic company information.

How many Travere Therapeutics (TVTX) shares does the CFO still own after the reported sale?

After the reported transactions, CFO Christopher R. Cline directly owned 111,226 shares of Travere Therapeutics common stock. This figure comes from the Form 4 table showing beneficial ownership following the February 4, 2026 sales, indicating he retains a significant equity position.

At what prices did the Travere Therapeutics CFO sell his TVTX shares?

The CFO sold 1,635 Travere Therapeutics shares at a weighted average price of $32.14, with individual trades ranging from $31.645 to $32.645, and another 110 shares at $32.90. These prices reflect open-market sales disclosed in the Form 4 footnotes and transaction table.

Did the Travere Therapeutics CFO sell shares to cover taxes on equity awards?

Yes. The filing explains that the sale includes shares sold to cover tax obligations arising when restricted stock units vested. This indicates part of the activity relates to routine tax withholding tied to equity compensation rather than purely discretionary share disposals.

Who authorized and signed the Travere Therapeutics Form 4 for the CFO’s stock sale?

The Form 4 reporting CFO Christopher R. Cline’s stock sales was signed by Elizabeth E. Reed as Attorney-in-Fact. This means she was authorized to sign the report on his behalf, a common practice when insiders grant power of attorney for SEC filing execution.